CANCER CELLS SHOW HIGH ENZYME LEVEL.Byline: Gina Kolata Gina Kolata (born in Baltimore, Maryland, February 25, 1948) is a science journalist for The New York Times. Her sister was the environmental activist Judi Bari. The New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of Times Scientists have found that many breast cancer cells have elevated levels of an enzyme associated with cell growth. Although the investigators, their university and a New York public relations public relations, activities and policies used to create public interest in a person, idea, product, institution, or business establishment. By its nature, public relations is devoted to serving particular interests by presenting them to the public in the most agency are promoting the findings as a major discovery of a possible switch that turns on cancer, some leading cancer researchers are less enthusiastic. They say it is neither a surprising finding, nor one that is clearly going to lend itself to better diagnosis or treatment of cancer. At a news conference in New York on Wednesday, the investigators, led by Dr. Craig C. Malbon of the State University of New York (body) State University of New York - (SUNY) The public university system of New York State, USA, with campuses throughout the state. at Stony Brook, announced that they had examined breast cells from 30 women, 11 of whom had breast cancer. They discovered that the enzyme, called mitogen-activated protein kinase Mitogen-activated protein (MAP) kinases (EC 2.7.11.24) are serine/threonine-specific protein kinases that respond to extracellular stimuli (mitogens) and regulate various cellular activities, such as gene expression, mitosis, differentiation, and cell survival/apoptosis. , or MAP kinase, is five to 20 times more abundant in cancerous breast cells than in noncancerous breast cells. A paper describing the work appears in the April issue of The Journal of Clinical Investigation The Journal of Clinical Investigation (JCI or J Clin Invest) is a leading biomedical journal, which is radically different from many of its peers in having a high impact factor (in 2006, 15.754) and offering all its contents entirely free. . ``It is the single molecule that must be turned on for a cell to go on to cell proliferation,'' Malbon said in a telephone interview. And so, he said, ``it provides a very strong and compelling argument for this to be the switch'' that allows a cancer cell to proliferate. But, cancer molecular biologists said, MAP kinase is a well-known enzyme that is associated with cell growth in general, so it is hardly surprising that it is found in high levels in cancer cells, which are growing rapidly. ``It is part of a pathway that is activated in many many cancer cells,'' said Dr. Arnold Levine, a cancer molecular biologist at Princeton University. High levels of the enzyme can arise from mutations in any of several genes known to cause cancer, Levine said. And so, he said, most investigators have focused on the genetic defects that are the primary causes of the cancers rather than looking for Looking for In the context of general equities, this describing a buy interest in which a dealer is asked to offer stock, often involving a capital commitment. Antithesis of in touch with. biochemical abnormalities that stem from these primary defects. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion